Evidence map›Paper›PMID 41279698›Full record

ArticlebioRxiv : the preprint server for biology2025

Empirical Evaluation of Single-Cell Foundation Models for Predicting Cancer Outcomes.

Haitham Elmarakeby, Ahmed Roman, Shreya Johri, Eliezer M Van Allen

Abstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Haitham ElmarakebyDana Farber Cancer Institute, Boston, MA, USA.ORCID 0000-0002-4315-4347
Ahmed RomanDana Farber Cancer Institute, Boston, MA, USA.
Shreya JohriDana Farber Cancer Institute, Boston, MA, USA.
Eliezer M Van AllenDana Farber Cancer Institute, Boston, MA, USA.ORCID 0000-0002-0201-4444

Funding

Molecular Determinants of Response and Resistance to EZH2 and PARP inhibition in Prostate CancerP50CA272390 · NCI · DANA-FARBER CANCER INST · PI Mark M. Pomerantz · 2023 to 2026
$12.0M
The Impact of DNA Damage Repair Abnormalities in Prostate CancerP01CA228696 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI OFFIT, KENNETH, POMERANTZ, MARK M. · 2019 to 2024
$8.7M
Dissecting Convergent Somatic and Germline Alterations that Mediate the Origins and Evolution of Kidney CancerR01CA278980 · NCI · DANA-FARBER CANCER INST · PI Eliezer M Van Allen · 2024 to 2026
$2.1M
NCI NIH HHS P01 CA228696NCI NIH HHS P50 CA272390NCI NIH HHS R01 CA278980
6 · The paper itself

Abstract

Foundation models pretrained on large-scale single-cell RNA sequencing data present a promising opportunity to advance translational cancer research. However, their utility in clinically relevant, patient-level applications of single-cell analysis remains underexplored. Here, we systematically evaluated nine emerging single-cell foundation models (scFMs) and three alternative baseline approaches across six cancer-specific tasks, ranging from subtype classification to treatment response prediction. We assessed model performance under zero-shot, continual training, and fine-tuning conditions, conducting 1,170 supervised and 130 unsupervised experiments. Our findings revealed that while current scFMs excel in certain analysis tasks, such as tumor microenvironment cell annotation, they had limited advantages in predicting clinical and biological outcomes of cancer patients compared to simpler baseline models. These insights highlight the critical role of evaluation on biologically and clinically relevant tasks in the responsible and impactful application of scFMs in precision oncology. They also emphasize the necessity of further methodological innovation and expanded cancer single-cell cohorts for the future development of scFMs.

Identifiers

PMID41279698
PMCPMC12637420

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.